PASG · Insider Trading
Passage Bio, Inc. Common Stock
Every open-market purchase and sale reported by PASG officers, directors and 10%+ beneficial owners on SEC Form 4, which must be filed within two business days of the transaction. Sales often reflect scheduled 10b5-1 plans or tax withholding rather than a directional view, so read counts alongside the size and the filer.
| Filed | Insider | Role | Type | Shares | Value |
|---|---|---|---|---|---|
| 2026-06-29 | Lynx1 Capital Management LP | 10%+ Owner | Buy | +100,110 | +$412.20K |
| 2026-05-21 | Sandip Kapadia | Director | A | +10,539 deriv. | — |
| 2026-05-21 | Dolan Sondhi | Director | A | +10,539 deriv. | — |
| 2026-05-21 | Athena Countouriotis | Director | A | +10,539 deriv. | — |
| 2026-05-21 | Thomas Richard Kassberg | Director | A | +10,539 deriv. | — |
| 2026-05-21 | Derrell Porter | Director | A | +10,539 deriv. | — |
| 2026-05-21 | Maxine Gowen | Director | A | +10,539 deriv. | — |
| 2026-03-18 | William Chou | PRESIDENT AND CEO | A | +58,000 deriv. | — |
| 2026-03-18 | Kathleen Borthwick | CFO | A | +15,610 deriv. | — |
| 2026-01-12 | William Chou | PRESIDENT AND CEO | MIXED | +5,924 | −$75.16K |
| 2026-01-12 | Kathleen Borthwick | CFO | MIXED | +2,938 | −$38.02K |
| 2025-12-29 | William Chou | PRESIDENT AND CEO | A | +20,000 deriv. | — |
| 2025-12-29 | Kathleen Borthwick | CFO | A | +10,000 deriv. | — |
| 2025-09-15 | Lynx1 Capital Management LP | 10%+ Owner | Buy | +64,016 | +$447.47K |
| 2025-07-24 | Lynx1 Capital Management LP | 10%+ Owner | Buy | +257,696 | +$1.47M |
| 2025-06-26 | OrbiMed Capital GP VII LLC | 10%+ Owner | Sell | −1,167,314 | −$394.48K |
| 2025-05-30 | Derrell Porter | Director | A | +201,857 deriv. | — |
| 2025-05-30 | Dolan Sondhi | Director | A | +201,857 deriv. | — |
| 2025-05-30 | Sandip Kapadia | Director | A | +201,857 deriv. | — |
| 2025-05-30 | Maxine Gowen | Director | A | +201,857 deriv. | — |
| 2025-05-30 | Thomas Richard Kassberg | Director | A | +143,789 deriv. | — |
| 2025-05-30 | Saqib Islam | Director | A | +201,857 deriv. | — |
| 2025-05-30 | Athena Countouriotis | Director | A | +201,857 deriv. | — |
| 2025-04-24 | OrbiMed Capital GP VII LLC | 10%+ Owner | Sell | −471,144 | −$157.46K |
| 2025-04-17 | OrbiMed Capital GP VII LLC | 10%+ Owner | Sell | −298,108 | −$99.41K |
| 2025-03-18 | Kathleen Borthwick | CFO | A | +278,386 deriv. | — |
| 2025-03-18 | Edgar B. Cale | GC & CORPORATE SECRETARY | A | +278,386 deriv. | — |
| 2025-03-18 | William Chou | PRESIDENT AND CEO | A | +779,533 deriv. | — |
| 2025-02-12 | Kathleen Borthwick | CFO | MIXED | +4,817 | −$1.69K |
| 2025-01-14 | OrbiMed Capital GP VII LLC | 10%+ Owner | Sell | −446,438 | −$284.45K |
| 2025-01-08 | OrbiMed Capital GP VII LLC | 10%+ Owner | Sell | −294,048 | −$206.61K |
| 2024-12-31 | Lynx1 Capital Management LP | 10%+ Owner | Buy | +747,290 | +$482.08K |
| 2024-12-26 | OrbiMed Capital GP VII LLC | 10%+ Owner | Sell | −460,642 | −$276.39K |
| 2024-12-11 | OrbiMed Capital GP VII LLC | 10%+ Owner | Sell | −124,552 | −$103.98K |
| 2024-12-06 | ORBIMED ADVISORS LLC | 10%+ Owner | Sell | −194,206 | −$154.68K |
| 2024-11-27 | Lynx1 Capital Management LP | 10%+ Owner | Buy | +912,706 | +$569.04K |
| 2024-10-02 | Edgar B. Cale | GC & CORPORATE SECRETARY | A | +50,000 deriv. | — |
| 2024-10-02 | Thomas Richard Kassberg | Director | A | +174,139 deriv. | — |
| 2024-09-23 | OrbiMed Capital GP VII LLC | 10%+ Owner | Sell | −78,600 | −$55.81K |
| 2024-09-18 | OrbiMed Capital GP VII LLC | 10%+ Owner | Sell | −400,262 | −$293.45K |
| 2024-05-23 | Sandip Kapadia | Director | A | +47,693 deriv. | — |
| 2024-05-23 | Maxine Gowen | Director | A | +47,693 deriv. | — |
| 2024-05-23 | Saqib Islam | Director | A | +47,693 deriv. | — |
| 2024-05-23 | Athena Countouriotis | Director | A | +47,693 deriv. | — |
| 2024-05-23 | Dolan Sondhi | Director | A | +39,092 deriv. | — |
| 2024-05-23 | Derrell Porter | Director | A | +47,693 deriv. | — |
| 2024-03-19 | William Chou | PRESIDENT AND CEO | A | +575,000 deriv. | — |
| 2024-03-19 | Kathleen Borthwick | CFO | A | +227,000 deriv. | — |
| 2024-03-19 | Mark S Forman | CHIEF MEDICAL OFFICER | A | +203,000 deriv. | — |
| 2024-03-19 | Edgar B. Cale | GC & CORPORATE SECRETARY | A | +203,000 deriv. | — |
| Insider | Role | Shares Held | Value |
|---|---|---|---|
| Lynx1 Capital Management LP | 10%+ Owner | 673,759 | $2.26M |
| ORBIMED ADVISORS LLC | 10%+ Owner | 385,918 | $1.30M |
| OrbiMed Capital GP VII LLC | 10%+ Owner | 313,980 | $1.05M |
| William Chou | PRESIDENT AND CEO | 10,600 | $35.60K |
| Kathleen Borthwick | CFO | 5,402 | $18.14K |
| Edgar B. Cale | GC & CORPORATE SECRETARY | 3,090 | $10.38K |
| Athena Countouriotis | Director | 945 | $3.17K |
| Saqib Islam | Director | 250 | $840 |
Form 4 reports a change in beneficial ownership by an officer, director or 10%+ holder, and must be filed within two business days of the transaction — so this is close to real time, unlike the 45-day-lagged 13F institutional data.
Transaction codes matter more than the raw buy/sell count. Code P is an open-market purchase — an insider choosing to buy with their own money, which is the signal most research treats as informative. Code S is a sale, but sales are frequently pre-scheduled under a 10b5-1 plan or cover tax withholding on vesting equity, so a run of sales often says nothing directional. Codes A and M are grants and option exercises rather than open-market decisions.
Full filing history and per-insider positions are on the PASG quote page; the site-wide leaderboard is on the insider transactions hub.
Market data may be delayed, incomplete, or inaccurate. Not a recommendation to buy, sell, or hold any security. Verify quotes with your broker before trading. See Terms §17.